Active, not recruitingNCT06483997
Diet, Hepcidin, and Chemotherapy RDI
Studying Primary peritoneal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- George Washington University
- Principal Investigator
- Kim Robien, PhD, RDMilken Institute School of Public Health, George Washington University
- Enrollment
- 100 target
- Eligibility
- 21 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (1)
- George Washington University Cancer Center, Washington D.C., District of Columbia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06483997 on ClinicalTrials.govOther trials for Primary peritoneal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07589543Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian CancerBeijing Biotech
- RECRUITINGPHASE2NCT07586826Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsPeking University People's Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02726997Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)M.D. Anderson Cancer Center